Combination CF Drugs Formoterol + Methacholine May Improve Mucus Clearance
Combining formoterol and methacholine significantly improves mucociliary clearance in animal models of cystic fibrosis, compared to using either drug alone.
Combining formoterol and methacholine significantly improves mucociliary clearance in animal models of cystic fibrosis, compared to using either drug alone.
Combining formoterol and methacholine significantly improves mucociliary clearance in animal models of cystic fibrosis, compared to using either drug alone.
Read MoreA 28-year-old cystic fibrosis patient underwent a 36-hour quadruple organ transplant for both lungs, a liver, and a kidney from a single donor.
Read MoreNew research indicates that baseline lung health is a stronger predictor of SARS-CoV-2 outcomes in cystic fibrosis transplantation patients than the time elapsed since transplantation.
Read MoreNew label extensions for Alyftrek and Trikafta make approximately 95% of the cystic fibrosis population in the United States eligible for treatment.
Read MoreResearchers developed lipid nanoparticles capable of inserting a full healthy CFTR gene into lab-grown human airway cells with severe cystic fibrosis.
Read MoreThe Quantitative Mucin Index (MUCQ) of the Lung analyzes sputum and other lung mucus samples to detect airway mucus abnormalities, assess disease risk, and track disease progression in patients over time.
Read MoreResearchers assessed salt intake in cystic fibrosis patients undergoing treatment with CFTR modulators, which improve salt conservation and other physiological markers.
Read MoreA new report shows steady progress in identifying cystic fibrosis earlier, with 67% of CF infants screened in 2024 within the first 28 days of life, compared to 60% in 2014.
Read MoreUK patients with cystic fibrosis are being hit hard by a wave of influenza in the country.
Read MoreERS leaders are calling for health systems to prioritize and integrate the care of chronic respiratory diseases (CRDs) across Europe.
Read MoreMore than a dozen national organizations are pressing Congress to support the Supplemental Oxygen Access Reform (SOAR) Act, which would ensure Medicare patient access to life-saving oxygen therapy.
Read MoreA new drug delivery system transports genetic therapies directly to the lungs, opening promising possibilities for patients with conditions like lung cancer and cystic fibrosis.
Read MoreEngland’s National Institute for Health and Care Excellence issued a positive final draft recommendation for Vertex Pharma’s Alyftrek CFTR modulator, which will now be available via the National Health Service (NHS).
Read MoreAlyftrek is a triple combination CFTR modulator comprised of deutivacaftor, tezacaftor and vanzacaftor.
Read MoreA closer look at suction and secretion clearance devices from ABM Respiratory, Baxter, Neotech, Philips, Precision Medical, Sentec, Seoil Pacific, and Tactile Medical.
Read MorePhage therapy—the use of viruses, or phages, to target and kill bacteria—improved lung function and reduced sputum P. aeruginosa in patients with cystic fibrosis.
Read MoreRT’s April-May 2025 issue looks at the importance of detecting abnormal lung function in cystic fibrosis patients, skills RTs must possess to successfully intubate a difficult airway, and more.
Read MoreChanges in lung function are of critical importance to patients with cystic fibrosis (CF), as lung function is a key indicator of disease progression and treatment effectiveness.
Read MoreThe CF Foundation’s Newborn Screening Committee developed a consensus guideline with seven recommendations to describe current best practices in newborn screening nationwide.
Read MoreFunding from the Cystic Fibrosis Foundation will support development of a breath test to diagnose Pseudomonas aeruginosa infections in CF patients.
Read MoreResearchers say a CF diagnosis within 10 days of birth compared to diagnosis within 6 weeks of birth can produce better height and weight outcomes.
Read MoreFunds from NIH will advance ALX1 as a potential treatment in cystic fibrosis and other chronic lung diseases.
Read MoreThe Simeox 200 is intended to promote and improve bronchial drainage by using high-frequency oscillatory vibrations and intermittent negative pressure.
Read MoreCystic fibrosis patients with elevated levels of bacteria infected by Pf phage in their sputum experience a faster decline in lung function.
Read More